Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07469982) titled 'A Phase I Study of SY-9453 in Patients With Advanced Solid Tumors' on March 3.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Shouyao Holdings (Beijing) Co. LTD

Condition: Advanced or Metastatic Solid Tumors With Homozygous MTAP Deletion

Intervention: Drug: SY-9453

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: February 2026

Target Sample Size: 122

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07469982 ...